Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.
American Society of Nephrology Oct 26 2024 Glucagon -like peptide-1-receptor agonists are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure . Reports of GLP-1RA–associated acute kidney injury have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies.
For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over a 1-year period. Among 14,783 patients, 9% were treated with a GLP-1RA while taking ant-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.
Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during administration of anti-cancer therapy. We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer.
Cancer Diabetes Drugs Kidney Cancer Therapy Congestive Heart Failure Glucagon Glucagon-Like Peptide-1 Heart Heart Failure Nephrology Receptor Research Type 2 Diabetes
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Dietitians boost GLP-1 therapy success with personalized care and side effect managementResearchers reveal the importance of personalized communication and side effect management in improving outcomes for patients on GLP-1 medications for weight management. The study highlights the critical role of dietitians in guiding lifestyle and dietary changes.
Read more »
Expanding access to GLP-1 weight-loss drugs could save thousands of livesResearchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates and addressing health inequities. Current drug uptake levels prevent far fewer deaths.
Read more »
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammationResearch highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking metabolic health to cognitive function. It suggests potential therapies for neurodegenerative diseases like Alzheimer's.
Read more »
Surge in GLP-1 drug use for obesity coincides with drop in bariatric surgeryResearchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.
Read more »
Anti-obesity medication 'tied to lower risk of suicidal thoughts'Researchers said their findings about GLP-1 receptor agonists should be interpreted with caution
Read more »
Aki Seiuli: Dragons bring back Samoa prop as injury coverDragons bring back Samoa's Aki Seiuli as short-term cover to help solve their loose-head prop injury crisis.
Read more »